ArticleJournal of thoracic disease2026

Immune checkpoint inhibitors (ICIs) for second-line retreatment in esophageal cancer progressing after first-line immunotherapy: a single-center retrospective cohort study.

Yixin Kang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.